BACKGROUND: Segmental bone loss remains a challenging clinical problem. A frequent mitigating factor is inadequate blood supply. Small molecules that activate the hypoxia-inducible factor pathway can be used to stimulate angiogenesis. We investigated an approach to promote healing using angiogenic and osteogenic compounds in combination with a biodegradable, weightbearing scaffold. METHODS: Adult rats underwent removal of a 5-mm segment of femur stabilized by a cylindrical biodegradable implant and intramedullary fixation. Treatment groups included 1) saline (negative control); 2) desferrioxamine (DFO, a hypoxia-inducible factor activator; 3) low-dose recombinant human bone morphogenetic protein-2 (rhBMP-2) (5 μg); 4) DFO and low-dose rhBMP-2 (5 μg); or 5) rh-BMP-2 (10 μg). Angiography was used to evaluate vascularity. Bone healing was assessed by radiographs, microcomputed tomography, histology, and biomechanical testing. RESULTS: Increased vascularity was seen at 6 weeks in the DFO treatment group. There appeared to be increased bone bridging as assessed by radiographic scores and microcomputed tomography in the BMP groups, although the quantification of bone volume did not show statistically significant differences. Biomechanical testing revealed improved stiffness in the treatment groups. CONCLUSIONS: DFO improved angiogenesis and stiffness of bone healing in segmental defects. BMP improved radiographic scores and stiffness. Use of angiogenic compounds in segmental bone loss is promising. CLINICAL RELEVANCE: Activation of the hypoxia-inducible factor pathway may prove useful for bone defects, particularly where impaired blood supply exists.The low-cost approach could be useful in segmental bone defects clinically.
BACKGROUND:Segmental bone loss remains a challenging clinical problem. A frequent mitigating factor is inadequate blood supply. Small molecules that activate the hypoxia-inducible factor pathway can be used to stimulate angiogenesis. We investigated an approach to promote healing using angiogenic and osteogenic compounds in combination with a biodegradable, weightbearing scaffold. METHODS: Adult rats underwent removal of a 5-mm segment of femur stabilized by a cylindrical biodegradable implant and intramedullary fixation. Treatment groups included 1) saline (negative control); 2) desferrioxamine (DFO, a hypoxia-inducible factor activator; 3) low-dose recombinant humanbone morphogenetic protein-2 (rhBMP-2) (5 μg); 4) DFO and low-dose rhBMP-2 (5 μg); or 5) rh-BMP-2 (10 μg). Angiography was used to evaluate vascularity. Bone healing was assessed by radiographs, microcomputed tomography, histology, and biomechanical testing. RESULTS: Increased vascularity was seen at 6 weeks in the DFO treatment group. There appeared to be increased bone bridging as assessed by radiographic scores and microcomputed tomography in the BMP groups, although the quantification of bone volume did not show statistically significant differences. Biomechanical testing revealed improved stiffness in the treatment groups. CONCLUSIONS:DFO improved angiogenesis and stiffness of bone healing in segmental defects. BMP improved radiographic scores and stiffness. Use of angiogenic compounds in segmental bone loss is promising. CLINICAL RELEVANCE: Activation of the hypoxia-inducible factor pathway may prove useful for bone defects, particularly where impaired blood supply exists.The low-cost approach could be useful in segmental bone defects clinically.
Authors: Rena L Stewart; Joseph T Cox; David Volgas; James Stannard; Lynn Duffy; Ken B Waites; Tien-Min Chu Journal: J Orthop Trauma Date: 2010-09 Impact factor: 2.512
Authors: Tiina M Asikainen; Aftab Ahmad; Barbara K Schneider; Wen-Bin Ho; Michael Arend; Mitchell Brenner; Volkmar Günzler; Carl W White Journal: Free Radic Biol Med Date: 2005-04-15 Impact factor: 7.376
Authors: John Street; Min Bao; Leo deGuzman; Stuart Bunting; Franklin V Peale; Napoleone Ferrara; Hope Steinmetz; John Hoeffel; Jeffrey L Cleland; Ann Daugherty; Nicholas van Bruggen; H Paul Redmond; Richard A D Carano; Ellen H Filvaroff Journal: Proc Natl Acad Sci U S A Date: 2002-07-12 Impact factor: 11.205
Authors: Xing Shen; Chao Wan; Girish Ramaswamy; Mahendra Mavalli; Ying Wang; Craig L Duvall; Lian Fu Deng; Robert E Guldberg; Alan Eberhart; Thomas L Clemens; Shawn R Gilbert Journal: J Orthop Res Date: 2009-10 Impact factor: 3.494
Authors: Hope B Pearson; Devon E Mason; Christopher D Kegelman; Liming Zhao; James H Dawahare; Melissa A Kacena; Joel D Boerckel Journal: Tissue Eng Part A Date: 2019-06-14 Impact factor: 3.845
Authors: Nicoleta L Popa; Jon E Wergedal; K-H William Lau; Subburaman Mohan; Charles H Rundle Journal: J Bone Miner Metab Date: 2013-05-23 Impact factor: 2.626
Authors: Shawn R Gilbert; Justin Camara; Richard Camara; Lynn Duffy; Ken Waites; Hyunki Kim; Kurt Zinn Journal: Bone Res Date: 2015-01-27 Impact factor: 13.567